In a letter to Londonwide LMCs' members yesterday, Dr Drage said her new name is Michelle.
‘I am writing to inform you that after careful consideration and thought and with the support of my family, friends and colleagues, my name and gender has changed permanently from Stewart Drage to Michelle Drage with immediate effect,’ the letter says.
Dr Drage is also joint chief executive of Londonwide LMCs.
Despite standing for re-election as a negotiator at yesterday's meeting in London, Dr Drage lost out to Devon GP Dr Beth McCarron-Nash. The rest of the negotiating team remains unchanged.
Dr Drage said: 'Congratulations to Peter (Holden), Beth and Richard (Vautrey) and whilst it is disappointing for me personally, they can be assured of my continued support as an active member of the GPC.
'As joint chief executive officer of Londonwide LMCs I, along with my colleague Dr Tony Stanton, have a huge amount of work to do to ensure that general practice is not destabilised as a result of the major changes being planned and implemented across London's NHS. There will always be another election.'
Full text of Dr Drage's letter
Editor's blog: A gender for change
Comment below and tell us what you think
What will Lord Darzi's NHS blueprint mean for practice and community nurses? Julie Griffiths investi... Read More
In the wake of the NHS's 60th birthday celebrations, Jenny Peters reflects on standards of cleanline... Read More
Singing workshops for mental health service users can promote social inclusion, writes Sarah Wild. Read More
Contributed by Dr Matthew Litchfield, GP, Nottingham and Dr James Milledge, retired consultant respi... Read more
Contributed by Mr David Walker, consultant obstetrician and gynaecologist at the Royal United Hospit... Read more
Contributed by Dr Unni Krishnan, clinical research fellow in cardiology at the Glenfield Hospital, L... Read more
GSK has launched Volibris (ambrisentan) for the treatment of pulmonary arterial hypertension (WHO Cl... Read more
Thymoglobuline is an immunosuppressant for the prophylaxis of graft rejection in renal or heart tra... Read more
Tyverb (lapatinib) is an oral antineoplastic agent that may provide women with an alternative option... Read more
This site is intended for healthcare professionals only
Comments
Rupen Kulkarni
17/07/2008
No comment.
Only registered users may comment. Log in now or register for a free account.